NKGN•NKGen Biotech Korea filed a corrected half-year report for the six months ended June 30, 2026, adding details on 5,323 treasury shares and a Sept. 5, 2027 cancellation deadline for shares acquired before a March 6, 2026 law change.
NKGen Biotech Korea filed a corrected semi-annual report for the six months ended June 30, 2026, to add an omitted treasury share report attachment. It disclosed holdings of 5,323 common shares, including 360 shares from merger-related appraisal rights and 4,963 undelivered shares tied to rehabilitation debt repayment. The company set Sept. 5, 2027, as the statutory cancellation deadline for treasury shares acquired before the March 6, 2026, law change.
